94 results about "Nuclear medicine imaging" patented technology

The invention relates to the field of radiopharmaceutical labeling, in particular to a probe precursor and a probe for targeting a CXCR4 receptor as well as a preparation method and application of the probe. After the probe precursor for targeting the CXCR4 receptor provided by the invention is combined with radionuclide, the CXCR4 receptor can be accurately positioned in vivo, the in-vivo targeting performance is excellent, and the purpose of tumor molecular imaging is achieved through nuclear medicine imaging. The structural formula of the probe precursor for targeting the CXCR4 receptor is as shown in the formula (I): # imgabs0 # formula (I).

The invention discloses a multi-metal borate nano-particle as well as a preparation method and application thereof. The preparation method comprises the following steps: in the presence of small molecules with alkyl chains, performing high-temperature thermal decomposition on an organic metal compound or a metal salt compound precursor and organic borate in a solvent, and then centrifuging, modifying, performing ultrafiltration, dialyzing and purifying to obtain the multi-metal borate nanoparticles. The preparation method disclosed by the invention has the characteristics of mildness, high efficiency and strong controllability. The multi-metal borate nanoparticles prepared by the preparation method disclosed by the invention have the advantages of monodisperse size, relatively high magnetic property and good biocompatibility. Therefore, the prepared multi-metal borate nanoparticles not only have multi-modal imaging functions such as magnetic resonance imaging, near-infrared two-region imaging, nuclear medicine imaging and magnetic particle imaging, but also can be used for various treatment means such as magnetocaloric therapy and boron neutron capture therapy; potential advantages are realized in biomedical applications such as magnetic targeting tumor treatment and imaging contrast agents, and high practical values are realized.

The invention relates to the technical field of medical imaging, in particular to a nuclear medicine imaging method and system, and the method comprises the steps: patient preparation, tracer agent distribution detection, image enhancement, multi-target dynamic imaging, image quantitative analysis and data fusion, and result output and diagnosis suggestion. A preliminary image of tracer agent distribution in the body of a patient is obtained through a multi-modal imaging device, a high-resolution image is generated through a convolutional neural network noise suppression algorithm, a contrast ratio self-adaptive enhancement algorithm and a super-resolution reconstruction algorithm based on a generative adversarial network, and accurate dynamic analysis is carried out. In combination with a random forest algorithm and a time sequence analysis model, performing quantitative analysis on the radioactive intensity, the volume and the metabolic rate of the target spot, and generating personalized diagnosis suggestions; according to the invention, the precision and diagnosis effect of nuclear medicine imaging are greatly improved, and the method is suitable for early diagnosis, curative effect evaluation and disease progress monitoring of clinical diseases.

A system, device and method of imaging using a real-time, AI-enabled analysis device coupled to an imaging device during an image scan of a subject includes: receiving data corresponding to a plurality of image frames from the imaging device and user input identifying a region of interest (ROI) in a first image frame; providing data corresponding to the first image frame, including the identified ROI and data corresponding to the remaining image frames to the AI-enabled data processing system; accepting a plurality of valid image frames from the plurality of image frames based on a predefined set of computer vision rules and a minimum accepted frame threshold; calculating, frame by frame, an ROI function value of the plurality of valid image frames; determining whether a predetermined ROI function value has been reached; and alerting an operator of the imaging device that the predetermined ROI function value has been reached.

The invention provides a rare earth silicon germanate scintillating material and a preparation method and application thereof, in particular to a rare earth silicon germanate scintillating material with high thermal stability and strong radiation resistance and a preparation method and application thereof, the general formula of the rare earth silicon germanate scintillating material with high thermal stability and strong radiation resistance is RE2 (1-x-delta / 2) Ce2xGedeltaSi (1-y + delta) Gey-deltaOz, in the formula, 0 lt; x is more than or equal to 0.05, y is more than or equal to 0.15 and less than or equal to 0.5, delta is more than or equal to 0 and less than or equal to 10 <-4 >, z is more than or equal to 4.95 and less than or equal to 5.05, RE represents a rare earth element, and the rare earth element is selected from at least one of lanthanum (La), lutetium (Lu), yttrium (Y) and gadolinium (Gd). The rare earth silicon germanate scintillating material provided by the invention has the characteristics of strong radiation damage resistance, high scintillation light output, low afterglow and the like while greatly improving the thermal stability, and can be used in occasions with extremely high requirements on the thermal stability or radiation resistance of the material, such as high-energy physical experiments, nuclear medicine imaging, oil exploration wells and the like.

The invention relates to a PET / CT (positron emission tomography / computed tomography) image breathing motion artifact correction method based on a triple subgroup convolutional network, and belongs to the field of nuclear medicine imaging. The invention provides a lightweight triple-subgroup convolution kernel, and the convolution kernel focuses on analyzing the rotation and translation characteristics of coronal planes, sagittal planes and cross sections closely related to PET / CT images so as to realize efficient detail analysis under the condition of clinical small samples. And then, a Transform-subgroup convolution fusion encoder and a pyramid network are constructed in combination, a constructed triple subgroup convolution registration network can combine sub-deformation fields of multiple dimensions to obtain a smooth deformation field, and the deformation field is used for spatial distortion transformation to achieve the purpose of artifact correction. According to the method, artifact correction experiment comparison is carried out by using pixel body membrane simulation data and clinical data, the superiority of the method in the aspects of robustness and generalization ability is proved, and the quality of PET / CT images is effectively improved.

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.

The invention relates to the technical field of radiopharmaceutical labeling, in particular to a compound targeting a DDR1 receptor and a radioactive tracer derived from the compound. According to the present invention, the radioactive tracer agent generated after the mixing reaction of the DDR1 receptor targeting compound and the radionuclide has strong receptor binding force with the DDR1 receptor, can accurately position the DDR1 receptor in vivo, has excellent in-vivo targeting performance, and can achieve the tumor molecular imaging purpose through nuclear medicine imaging. The invention relates to a DDR1 receptor targeting compound, which has a structural formula as shown in a formula (I): # imgabs0 # formula (I).

The invention discloses a method for identifying and processing an artifact region in a nuclear medicine imaging image, and relates to the technical field of medical image registration. Comprising the following steps: S1, acquiring a PET dynamic image sequence, a CT dual-energy spectrum image and a respiratory movement monitoring signal, and generating a registration quality map; s2, the PET dynamic image sequence and the CT image are combined, statistical dependence between the PET dynamic image sequence and the CT image is obtained, and a focus of an artifact area in the CT image is positioned or reconstructed and compensated; and S3, carrying out artifact reconstruction on the optimized CT image, and processing a reconstructed artifact region through a double-branch network model. According to the method, the instantaneous phase of the respiratory signal is extracted through Hilbert transform, the PET dynamic image sequence is grouped according to the respiratory phase, accurate matching of same-phase frames can be achieved, meanwhile, the registration quality map is generated through the B-spline Demons algorithm, and organ deformation artifacts caused by respiratory movement can be remarkably reduced.

The invention relates to the technical field of nuclear medicine imaging agents, in particular to a GPC3-targeted compound, a radionuclide probe and application of the GPC3-targeted compound and the radionuclide probe. The compounds targeting GPC3 comprise a GBP polypeptide, optionally a linking group, a radionuclide chelating group, and optionally an albumin binding group; the linking group is a group formed by a linker, and the linker is selected from at least one of a hydrocarbon chain linker, a polyethylene glycol linker and an amino acid linker. The radionuclide probe disclosed by the invention can be applied to diagnosis and treatment of GPC3 positive hepatocellular carcinoma, and has the advantages of high sensitivity, relatively low non-specific tissue uptake and high tumor and normal liver tissue uptake ratio.

A system and method for the measurement of radiation emitted from the body, for example, is presented. In one example, radiation sensors (e.g., gamma radiation sensors) may be used to measure activity proximate an injection site as a function of time. In some embodiments, one or more rangefinders may be employed to determine a size and / or position of a subject relative to the radiation sensors to better account for varying material densities within the system in estimating, for example, the amount of radioactive material in the tissue proximate the injection site. With an estimated function of radioactive material proximate the injection site as a function of time known, an estimated arterial input function may be determined, allowing for calculation of a correction factor that may be applied by a clinician during nuclear medical imaging. The magnitude, location, and volume of the radioactive source in the body may also be estimated.

The utility model belongs to the technical field of nuclear medicine imaging, and discloses a cooling module and animal imaging equipment, the cooling module is used for cooling a probe module of the animal imaging equipment, the cooling module comprises a cooling base, a cooling main body and a control panel, the cooling base is provided with a first cooling cavity and is used for supporting and cooling a mainboard of the probe module, and the control panel is provided with a second cooling cavity. One end of the cooling body is connected with the side, away from the probe module, of the cooling base, a second cooling cavity is formed in the cooling body, and the control panel is attached to the surface of the cooling body and electrically connected with a mainboard of the probe module. The cooling module has a good heat dissipation effect on the probe module, and can timely dissipate heat generated when the mainboard of the probe module and the control panel of the equipment work, so that the imaging precision is ensured, and the service life of the probe module is prolonged.

The invention relates to a touch fluid neuron specific tracing imaging agent, a preparation method and application, and belongs to the technical field of nuclear medicine imaging, the tracing imaging agent is composed of a nerve tracer agent horseradish peroxidase (HRP), zirconium-89 isotope chelated by deferoxamine and a pharmaceutically acceptable carrier, the effective tracking window of the tracer agent is prolonged to 120 hours, and the effective tracking window of the tracer agent is prolonged to 120 hours. The multi-stage synaptic transfer period of the fluid touching neuron can be completely covered; the spatial resolution is improved by 5-8 times compared with that of traditional FDG-PET, and a fluid touching neuron cluster can be accurately presented; the in-vitro serum stability is excellent, the radiochemical purity is still larger than or equal to 80.5% within 120 hours, PET / MRI bimodal imaging can be adapted, drug administration is conducted through lateral ventricle minimally invasive injection, the probe is suitable for various animal models such as mice, rats and non-human primates, in-vivo dynamic tracing of sympathetic fluid neuron trans-synapses can be achieved on the premise that no tissue damage exists, and the probe has a good application prospect. And a key technical tool is provided for neural circuit analysis, neuroscience basic research and preclinical research of neurodegenerative diseases.

The utility model provides a wearable device capable of preventing urine leakage and used for nuclear medicine imaging examination. The wearable device is composed of a protective pad and a wearable structure. The protective pad comprises a waterproof bottom layer and a water-absorbing surface layer; the wearing structure is of a T-shaped structure and is composed of a wearing body, a left wing and a right wing, the two ends of the outer side of the lower edge of the wearable body are connected with the inner sides of the left wing and the right wing through first pasting areas. The rear part of the wearable structure is connected with the upper surface of the water-absorbing surface layer through a second pasting area; drawing structures are arranged at the upper end and the lower end of the protective pad and penetrated by drawing ropes. The radioactive urine absorption device can basically absorb radioactive urine overflowing from all examinees, so that the examination bed board is prevented from being subjected to radioactive contamination, radioactive secondary pollution can be prevented from being generated when a polluted wearing device is treated, and the structure of the radioactive urine absorption device is easy to disassemble and replace and convenient to use.

The invention belongs to the technical field of inorganic scintillator materials, and particularly relates to a multi-element co-doped yttrium lutetium silicate scintillator and a preparation method and application thereof, and the material has excellent comprehensive performance of high light output, short decay time, high radiation hardness, high matching degree of emission spectrum and novel photoelectric sensors and the like. The invention further relates to a preparation method of the scintillator material and application of the scintillator material in radiation detection fields such as positron emission tomography (PET), time flight PET (TOF-PET), interaction depth PET (DOI-PET), single photon emission computed tomography (SPECT), high-energy physical experiments, nuclear medicine imaging, industrial nondestructive inspection, safety detection (such as luggage and cargo container inspection) and the like.

The invention provides a nuclear medicine imaging adaptive control method and system based on a modular gamma probe, and relates to the technical field of nuclear medicine imaging. The method comprises the following steps: acquiring multi-scale signal features and identifying an uptake mode of current tracer agent distribution; dynamically adjusting the weight of the multi-scale signal characteristics in the positioning decision of the modular gamma probe array according to the identified characteristics of the shooting mode; after weight adjustment is completed, an adjustment instruction for the modular gamma probe array is generated and executed, the modular gamma probes are controlled to collect data, image data are obtained, and a diagnosis image is reconstructed. The method aims to solve the problem that the image quality is reduced due to data blurring and system misjudgment in an existing self-adaptive control method, and effectively inhibits the acquisition efficiency degradation caused by the difference of imaged objects, so that the diagnosis image quality is improved, artifacts and blurring are reduced, and the reliability and diagnosis accuracy of nuclear medicine imaging are enhanced.

The present invention relates to the technical field of molecular imaging probes, and particularly relates to a molecular imaging probe labeling precursor targeting the DDR1 receptor, a probe thereof, and a preparation method and application thereof. The molecular imaging probe labeling precursor targeting the DDR1 receptor provided by the present invention reacts with a radionuclide to generate a molecular imaging probe targeting the DDR1 receptor, which has a strong receptor binding force with the DDR1 receptor, can accurately locate the DDR1 receptor in vivo, has excellent in vivo targeting performance, and realizes the purpose of tumor molecular imaging through nuclear medicine imaging. Compared with the radioactive tracer [68Ga]Ga-SDUHYX01, the molecular imaging probe [68Ga]Ga-SDUHYX04 optimizes the molecular structure, reduces the lipophilicity, adjusts the metabolic pathway of the molecular imaging probe, thereby making the tumor-to-liver ratio of the molecular imaging probe higher, and also showing excellent imaging effects at 60 minutes.

The invention discloses a detector which is not provided with an external collimator and can be used for SPECT (single photon emission computed tomography) and PET (positron emission tomography). The detector comprises a crystal unit and a photoelectric detection layer, a plurality of gaps are formed in the top of the crystal unit, the non-gap structure part in the crystal unit is used for blocking gamma photons emitted by SPECT nuclides, and the gaps are used for collimating the incident gamma photons emitted by the SPECT nuclides and then enabling the gamma photons to enter the bottom of the crystal unit; the photoelectric detection layer is used for detecting scintillation light excited by the gamma photons in the crystal unit and converting the scintillation light into electric signals. The imaging system comprises a plurality of detectors which are arranged according to a set rule. According to the invention, the problems of high cost, heavy system and lack of multi-nuclide simultaneous imaging capability of traditional nuclear medicine imaging are solved, and a solution is expected to be provided for a next-generation high-performance PET / SPECT / CT scanner.

The invention provides an azobenzothiazole compound and a preparation method thereof, a pharmaceutical composition and application thereof, and a nuclear medicine imaging agent, and belongs to the technical field of medicines. The azobenzothiazole compound provided by the invention has a structure as shown in a formula I. The azobenzothiazole compound provided by the invention has good affinity to the alpha-synuclein aggregate, and can be used for preparing a medicine for detecting the alpha-synuclein aggregate in a tissue sample. Meanwhile, a fluorine-18 marker obtained after the azobenzothiazole compound is labeled with radioisotope fluorine-18 can be used for nuclear medicine imaging, and the fluorine-18 marker can be used for functional imaging of intracerebral alpha-synuclein aggregates, such as intracerebral alpha-synuclein aggregates, intracerebral alpha-synuclein aggregates, intracerebral alpha-synuclein aggregates and intracerebral alpha-synuclein aggregates. The alpha-synuclein is suitable for being used as a radiodiagnosis medicine for cerebral neurodegenerative diseases or other related diseases taking the alpha-synuclein aggregate as a pathological marker. # imgabs0 #

The utility model belongs to the technical field of nuclear medicine imaging, and discloses a probe module and animal imaging equipment, the probe module comprises a main board, a protective cover and a fixing structural member, the main board is provided with a plurality of probe units, the protective cover is provided with an opening side, the protective cover and the main board define a protective cavity, the plurality of probe units are located in the protective cavity, and the fixing structural member is located in the protective cavity. The fixing structural member is arranged on the side, away from the probe unit, of the main board and connected with the opening side, and the fixing structural member is used for fixing the probe module to the cooling base. The probe module is easy to assemble and convenient to install, the protective cover is not prone to deformation, and the protection and shielding effects on the probe unit are good.

The present invention discloses EphA2 targeting polypeptides and their applications. These high-affinity polypeptides can specifically bind to a variety of tumor cells, preferably liver cancer, breast cancer, lung cancer, colorectal cancer, glioma, pancreatic cancer, and prostate cancer. The high-affinity characteristics of the targeting peptides can be used for optical imaging and nuclear medicine imaging of malignant tumors. These high-affinity polypeptide monomers, polypeptide dimers or polypeptide polymers can be directly or indirectly coupled with fluorescent dyes to serve as tumor-specific targeting molecular probes, which are expected to achieve the effect of accurately locating the tumor boundary, and can bring real-time performance to preoperative and intraoperative image navigation, with the advantage of improving surgical accuracy. This series of polypeptide monomers, dimers or polymers can also be coupled with radionuclides to detect malignant tumors in real time in vivo, so as to achieve the purpose of disease diagnosis or treatment.

This utility model discloses a prostate cancer imaging device based on nuclear medicine imaging, comprising: a base, a bed board disposed on top of the base, and an imaging mechanism disposed on top of the bed board; a tilt adjustment component is disposed between the base and the bed board; the tilt adjustment component includes: a semi-cylinder fixed to the top of the base, and a semi-worm gear fixed to the top of the semi-cylinder. By disposing of the tilt adjustment component between the base and the bed board, when the patient lies on the bed board and the imaging posture needs to change at a certain angle from the supine posture, the bed board can be tilted relative to the base at a certain angle through the cooperation of a first servo motor, a worm gear, a semi-worm gear, several swing blocks, a limiting groove, several fixing rings, and limiting components. This eliminates the need for the patient to adjust their supine posture to achieve the required imaging posture, while also providing convenience for patients with limited mobility, thereby improving the practicality of the device.

The present invention relates to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to imidazothiadiazole compounds as well as a preparation method therefor and the use thereof. The compounds are shown as general structural formula (I). After being labeled with a suitable radioisotope, the compounds and derivatives thereof can perform nuclear medicine imaging on α-synuclein aggregates in the brain, so as to assist in clinical diagnosis of synuclein diseases including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and some rare diseases.

The present invention relates to the fields of high molecular heterocyclic compounds and nuclear medicine imaging technology, and particularly relates to a PET probe obtained by coupling an SSTR agonist and an inhibitor, and a preparation method and application thereof. The PET molecular probe comprises a targeting molecule obtained by coupling an SSTR agonist and an inhibitor, a radioisotope, and a linker, and the linker connects the targeting molecule and the radioisotope. The heterodimer obtained by coupling the SSTR agonist and the inhibitor can improve the PET detection sensitivity by increasing the binding affinity with the target through a synergistic effect; has higher specificity and can specifically and efficiently target SSTR for in vivo imaging in a variety of tumor microenvironments; not only makes the distribution of the radioligand more uniform, but also can effectively improve the clinical effect of radionuclide therapy after labeling with therapeutic radionuclides such as <supgt;177< / supgt;Lu. Compared with the prior art, the molecular probe has stronger affinity, higher stability and higher target-to-background ratio; meanwhile, the preparation method of the PET molecular probe is simple and stable, and has good market promotion and application prospects.

1. Name of the product in this design: Scintillation Detector. 2. Application of this design: This design is mainly used in fields such as nuclear medicine imaging, high-energy physics, environmental monitoring, security inspection, and gamma cameras for detecting the energy spectrum or position of X-rays or gamma rays. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. Design 1 is designated as the basic design.

The present invention belongs to the field of biomedical engineering, and specifically relates to a tumor affinity peptide for human epidermal growth factor receptor 2 and its application, wherein the tumor affinity peptide includes 6 sequences such as Leu-Arg-Leu-Ser-Gly-Gly-Hyp-Gln. Pharmacodynamic experiments have shown that the polypeptides of the present invention can be used in cancer diagnosis and treatment. These high-affinity polypeptides can specifically bind to a variety of tumor cells. The high-affinity characteristics of the targeting peptide can be used for optical imaging and nuclear medicine imaging of malignant tumors. These high-affinity polypeptide monomers, polypeptide dimers or polypeptide polymers can be directly or indirectly coupled with fluorescent dyes as tumor-specific targeting molecular probes, which are expected to achieve the effect of accurately locating the tumor boundary, and can bring real-time performance to preoperative and intraoperative image navigation, with the advantage of improving surgical accuracy. This series of polypeptide monomers, dimers or polymers can also be coupled with radionuclides to detect malignant tumors in real time in vivo to achieve the purpose of disease diagnosis or treatment.

The invention belongs to the technical field of nuclear medicine imaging, and discloses a radioactive tracer agent distribution quantification optimization method and related equipment, and the method comprises the steps: obtaining scanning bed deformation information, moving track information and physiological motion dynamic information of a patient, and obtaining a radioactive tracer agent distribution quantification optimization result based on the scanning bed deformation information, the moving track information and the physiological motion dynamic information; the method comprises the steps of constructing a multi-source error integrated influence model, performing radioactive tracer distribution reconstruction on original detection data through an OSEM algorithm based on the multi-source error integrated influence model to obtain real distribution information of a radioactive tracer, and performing calculation according to the real distribution information to obtain a standardized uptake value. By means of the method, the accuracy of the radioactive tracer agent distribution quantification result is improved.

The invention belongs to the technical field of nuclear medicine imaging, and particularly relates to a two-phase xenon positron tomography system and method.The two-phase xenon positron tomography system comprises a two-phase xenon detector module, a heat preservation device, a refrigeration purification system and a data acquisition system; the performance of the system is obviously improved by adopting a new material and a new method and correspondingly optimizing the system structure.

The present invention relates to the fields of medicinal chemistry, radiopharmaceutical chemistry, and clinical nuclear medicine, and in particular to a compound targeting CDK4 / 6 and a radioactive tracer derived therefrom. The CDK4 / 6-targeting compound has the structures shown in the following formulas (I) and (II). The radioactive tracer provided by the present invention has strong binding affinity with CDK4 / 6, can accurately locate CDK4 / 6 in vivo, exhibits excellent in vivo targeting performance, and achieves tumor molecular imaging through nuclear medicine imaging. Formula (I); Formula (II).

The present invention relates to the field of medical imaging technology, and specifically provides an analysis method, system, device, and medium for nuclear medicine imaging radiation reports. By correlating the extracted characteristic values of the patient's medical imaging data with the characteristic values of the patient's own historical medical imaging data, the comprehensive correlation coefficient between the patient's disease condition and their own historical medical imaging is evaluated, which can fully consider the individual trajectory of the patient's disease development. By correlating the extracted characteristic values of the patient's clinical data with the characteristic values of the clinical data of the same type of patient group, the population deviation degree of the patient's clinical data is calculated, making it more likely to detect new changes in the patient's condition at an early stage. Based on the comprehensive correlation coefficient between the patient's disease condition and their own historical medical imaging and the population deviation degree of the patient's clinical data, a model is constructed to predict the category of the patient's disease progression, enabling a more comprehensive analysis of the patient's condition and better management of the patient's disease process.